

A Phase 1b/2, Double-Blind, Placebo-Controlled, Randomized, Parallel-Arm Study to Explore the Safety, Pharmacokinetics, and Proof of Biological Activity of DS-7011a in Patients with Systemic Lupus Erythematosus and Active Cutaneous Lupus Erythematosus

Status: Recruiting

Eligibility Criteria

Sex: Male or Female

Age Group: 18 years and over

This study is NOT accepting healthy volunteers

Inclusion Criteria:

- Diagnosed with Lupus at least 6 months ago - active CLE (acute, subacute, and chronic cutaneous lupus), with active skin involvement - Body mass index (BMI) at least 18 kg/m and body weight at least 45 kg (99lbs.) - see link to clinicaltrials.gov for complete inclusion and exclusion criteria

Exclusion Criteria:

- history of cancer in the past 2 years - history of chronic, recurrent (3 or more of the same type of infection in 1 year) or recent serious infection including HIV, viral hepatitis, or shingles

Conditions & Interventions

Conditions:

Dermatology (Skin, Hair & Nails)

Keywords:

CLE, Lupus, SLE, Systemic Lupus Erythematosus

More Information

Description: The main purpose of this study is to gather information about DS-7011a, an investigational drug that may help to treat systemic lupus erythematosus (SLE), including cutaneous lupus erythematosus (CLE). Overall study duration for a participant is expected to be approximately 28 weeks.

Study Contact: Gretchen Bellefeuille - belle116@umn.edu

Principal Investigator: David Pearson

IRB

Number: SITE00002046

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.